Sangamo enters into asset sale agreements with Lilly and Astellas
Click here to view
Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at
https://www.veritaglobal.net/SangamoTherapeutics
.
Careers
Core Values
Open Positions
Employee Benefits
Clinical Trials
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
Modular Integrase (MINT) Platform
Therapeutic Applications
Neurology
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Small Fiber Neuropathy (SFN)
Fabry Disease
Hemophilia A
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
Modular Integrase (MINT) Platform
Therapeutic Applications
Neurology
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Small Fiber Neuropathy (SFN)
Fabry Disease
Hemophilia A
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
LinkedIn
Twitter
ESGCT 2023
Epigenetic Regulation for Neurology
Cell Therapy - Regulatory T-Cells (CAR-Tregs)
CAR-T in Oncology
Epigenetic Regulation for Neurology
ESGCT 2023
Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency
ESGCT 2023
Shank3 Gene Activation Mediated by Zinc Finger Activators (ZF-As) as a Therapeutic Approach for Phelan-McDermid Syndrome
Cell Therapy - Regulatory T-Cells (CAR-Tregs)
ESGCT 2023
Multimerization of Chimeric Antigen Receptor (CAR) binding domains: A solution to assess tissue specificity of low to medium affinity scFv
CAR-T in Oncology
ESGCT 2023
Multiplex targeting of immune checkpoints with compact zinc finger repressors to improve anti-tumor activity of T cells